AGCO is in a sustained, multi-month downtrend that has recently stabilized into a lower-range consolidation. The stock is down 4.77% over the trailing year and 2.00% year to date, but the more telling figure is its position within the 52-week range of $98.22 to $143.78: at $103.72 the shares sit at roughly 12% of that range, just above the 52-week low and far below the high. That positioning signals persistent distribution and a lack of buyers rather than an overextended momentum move; the stock is closer to a falling-knife profile than a value snap-back, and the -29.92% max drawdown confirms how deep the de-rating has been. Relative strength is uniformly negative, with a 1-year relative strength versus SPY of -20.30, meaning AGCO has surrendered more than 20 percentage points of performance to the index over twelve months.

Short-term momentum is decisively negative and diverging from an already weak longer-term trend. The stock is down 13.49% over the past month and 10.07% over three months, versus a 1-year decline of only 4.77%, which means the pace of decline has accelerated sharply in recent weeks. That acceleration is corroborated by the 1-month relative strength of -14.71 against a SPY that rose 1.22% over the same period, a stark divergence showing AGCO is falling while the broad market grinds higher. The most recent price action is especially weak: the stock fell from $116.19 on October 6 to $103.72 by October 16, a roughly 10.7% slide in eight sessions, with the final day down 2.34% on volume of about 713,000 shares, suggesting sellers remain in control and no capitulation-volume reversal has yet appeared.

Key technical levels are well defined. Support sits at the 52-week low of $98.22, roughly 5.3% below the current $103.72; a decisive break below that level would confirm a fresh leg lower and likely trigger momentum-driven selling, while a hold and reversal there would form a potential double-bottom base. Resistance is layered, with the 52-week high of $143.78 far overhead (about 38.6% above spot) and nearer supply in the $116-$122 zone where the stock repeatedly failed in September and early October. The beta of 1.074 indicates the stock moves roughly in line with the market, so the underperformance is company- and sector-specific rather than a high-beta amplification effect; for position sizing, the modest beta offers little cushion against the current idiosyncratic downtrend, and the 2.95 short ratio suggests short interest is meaningful but not extreme.

AGCO's revenue trajectory is stagnating rather than collapsing. Q2 2026 revenue of $2.6097 billion was down 0.96% year over year versus $2.635 billion in Q2 2025, following Q1 2026 revenue of $2.343 billion and Q4 2025 revenue of $2.920 billion. The multi-quarter pattern shows a seasonal peak in Q4 and a soft first half, with the year-over-year comparison essentially flat, indicating the agricultural equipment downcycle is bottoming rather than deepening. Within the mix, tractors remain the dominant revenue engine at roughly $1.669 billion, replacement parts contribute about $516 million of high-margin aftermarket revenue, and grain storage/protein systems are negligible at the reported segment level; the aftermarket parts stream is the most defensible growth lever, while new-tractor demand remains the swing factor tied to farmer income and crop prices.

Profitability is positive but compressed relative to the company's own history. Q2 2026 net income was $77.2 million on a 2.96% net margin, with gross profit of $645.9 million (24.75% gross margin) and operating income of $151.9 million (5.82% operating margin). Gross margin has been remarkably stable in a 24.3%-25.4% band over the past several quarters, but operating margin has deteriorated from 9.48% in Q4 2025 to 5.82% in Q2 2026, reflecting lower volume absorption and higher SG&A ($335.7 million) and R&D ($141.2 million) spend. The trailing net margin of 7.21% and operating margin of 6.93% are well below the 10.6% operating margin the company posted in 2023, underscoring that the earnings recovery thesis depends on volume leverage returning as the cycle turns.

Balance-sheet health is solid and cash generation is adequate but lumpy. Debt-to-equity is a conservative 0.63, the current ratio is 1.39, and interest coverage of roughly 8.9x provides comfortable cushion. Trailing free cash flow is $330.3 million, and the Q2 2026 quarter alone generated $108.2 million of FCF on $165.4 million of operating cash flow after $57.2 million of capex, a sharp swing from the -$455 million FCF in Q1 2026 that reflected a $521 million working-capital build. ROE of 17.0% and ROA of 3.47% show the equity base is still productive, and the company returned capital aggressively via $347 million of buybacks and $21 million of dividends in Q2; the main watch item is the elevated inventory (137.8 days of inventory outstanding) that could pressure cash conversion if demand stays soft.